Name: ANAPTYSBIO INC (ANAB) Stock
Brand: ANAPTYSBIO INC
Rating: 7 (3 reviews)

ANAB Latest News, Press Relases and Analysis

All

Press Releases

7 days ago - By: Chartmill

ANAPTYSBIO INC (NASDAQ:ANAB) Shows High-Growth Momentum and Positive Technical Setup

10 days ago - By: Benzinga - Mentions: GSK

AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study

10 days ago - By: Investor's Business Daily

Why AnaptysBio Stock Plummeted, Reversing A 70% Monthlong Run

10 days ago - By: AnaptysBio, Inc.

Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis

10 days ago - By: AnaptysBio, Inc.

Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis

15 days ago - By: Zacks Investment Research - Mentions: OVID

AnaptysBio, Inc. (ANAB) Surpasses Q3 Earnings and Revenue Estimates

15 days ago - By: AnaptysBio, Inc.

Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update

15 days ago - By: AnaptysBio, Inc.

Anaptys Announces Participation in November Investor Conferences

15 days ago - By: AnaptysBio, Inc.

Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update

15 days ago - By: AnaptysBio, Inc.

Anaptys Announces Participation in November Investor Conferences

22 days ago - By: Zacks Investment Research - Mentions: PCRX

Pacira (PCRX) Expected to Beat Earnings Estimates: Should You Buy?

22 days ago - By: AnaptysBio, Inc.

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

22 days ago - By: AnaptysBio, Inc.

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

a month ago - By: AnaptysBio, Inc.

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025

a month ago - By: AnaptysBio, Inc.

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025

2 months ago - By: Stocktwits - Mentions: VFMO UWM

AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level

2 months ago - By: AnaptysBio, Inc.

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

2 months ago - By: AnaptysBio, Inc.

Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14

2 months ago - By: AnaptysBio, Inc.

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

2 months ago - By: AnaptysBio, Inc.

Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14

2 months ago - By: Stocktwits - Mentions: LLY

Why Is Eli Lilly’s Stock Slipping Premarket?

3 months ago - By: AnaptysBio, Inc.

Anaptys Announces Participation in September Investor Conferences

3 months ago - By: AnaptysBio, Inc.

Anaptys Announces Participation in September Investor Conferences

3 months ago - By: Benzinga

Analyst Expectations For AnaptysBio's Future

4 months ago - By: The Motley Fool

AnaptysBio (ANAB) Q2 Revenue Jumps 103%

4 months ago - By: Zacks Investment Research - Mentions: AGEN

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

4 months ago - By: AnaptysBio, Inc.

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: AnaptysBio, Inc.

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

4 months ago - By: Zacks Investment Research - Mentions: ACIU

ANAPTYSBIO INC (ANAB) Stock News

ANAB Latest News, Press Relases and Analysis

ANAPTYSBIO INC (NASDAQ:ANAB) Shows High-Growth Momentum and Positive Technical Setup

AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study

Why AnaptysBio Stock Plummeted, Reversing A 70% Monthlong Run

Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis

Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis

AnaptysBio, Inc. (ANAB) Surpasses Q3 Earnings and Revenue Estimates

Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update

Anaptys Announces Participation in November Investor Conferences

Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update

Anaptys Announces Participation in November Investor Conferences

Pacira (PCRX) Expected to Beat Earnings Estimates: Should You Buy?

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025

AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14

Why Is Eli Lilly’s Stock Slipping Premarket?

Anaptys Announces Participation in September Investor Conferences

Anaptys Announces Participation in September Investor Conferences

Analyst Expectations For AnaptysBio's Future

AnaptysBio (ANAB) Q2 Revenue Jumps 103%

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

AC Immune (ACIU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release